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BACKGROUND AND PURPOSE
Developmental switches in NMDA receptor subunit expression have been inferred from studies of GluN2 expression levels,
changes in kinetics of glutamatergic synaptic currents and sensitivity of NMDA receptor-mediated currents to selective
GluN2B antagonists. Here we use TCN 213, a novel GluN2A-selective antagonist to identify the presence of this subunit in
functional NMDA receptors in developing cortical neurones.
EXPERIMENTAL APPROACH
Two-electrode voltage-clamp (TEVC) recordings were made from Xenopus laevis oocytes to determine the pharmacological
activity of TCN 213 at recombinant NMDA receptors. TCN 213 antagonism was studied in cultures of primary cortical
neurones, assessing the NMDA receptor dependency of NMDA-induced excitotoxicity and monitoring developmental switches
in NMDA receptor subunit composition.
KEY RESULTS
TCN 213 antagonism of GluN1/GluN2A NMDA receptors was dependent on glycine but independent of glutamate
concentrations in external recording solutions. Antagonism by TCN 213 was surmountable and gave a Schild plot with unity
slope. TCN 213 block of GluN1/GluN2B NMDA receptor-mediated currents was negligible. In cortical neurones, at a early
developmental stage predominantly expressing GluN2B-containing NMDA receptors, TCN 213 failed to antagonize NMDA
receptor-mediated currents or to prevent GluN2B-dependent, NMDA-induced excitoxicity. In older cultures (DIV 14) or in
neurones transfected with GluN2A subunits, TCN 213 antagonized NMDA-evoked currents. Block by TCN 213 of NMDA
currents inversely correlated with block by ifenprodil, a selective GluN2B antagonist.
CONCLUSIONS AND IMPLICATIONS
TCN 213 selectively blocked GluN1/GluN2A over GluN1/GluN2B NMDA receptors allowing direct dissection of functional
NMDA receptors and pharmacological profiling of developmental changes in native NMDA receptor subunit composition.
Abbreviations
5,7 DCKA, 5,7 dichlorokynurenic acid; DIV, days in vitro; TCN 213, N-(cyclohexylmethyl)-2-({5-[(phenylmethyl)amino]-
1,3,4-thiadiazol-2-yl}thio)acetamide; TEVC, two-electrode voltage clamp
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Introduction
NMDA receptors are a subclass of ligand-gated ion channels
activated by the CNS excitatory neurotransmitter L-glutamate
(receptor nomenclature follows Alexander et al. 2011). In
addition to their fundamental role in mediating the slow
component of the glutamatergic excitatory postsynaptic
potential/current, these receptors play pivotal roles in CNS
development, learning and memory and pathophysiology.
NMDA receptors are tetrameric proteins, the majority of
which comprise two GluN1 and two GluN2 subunits (see
Erreger et al., 2004, Chen and Wyllie, 2006; Traynelis et al.,
2010). The GluN1 subunit exists in eight isoforms that are
generated by alternative splicing of exons 5, 21 and 22 (Sugi-
hara et al., 1992) while GluN2A-D subunits are encoded by
four separate genes (Monyer et al., 1992). Uniquely among
the family of glutamate ionotropic receptors, NMDA recep-
tors require both glutamate and glycine (a co-agonist) to bind
to the receptor for channel activation to occur (Figure S1A;
Johnson and Ascher, 1987; Kleckner and Dingledine, 1988)
with the glycine binding site being formed by the S1 and S2
domains of the GluN1 subunit and glutamate binding site
being formed from the homologous regions on the GluN2
subunit. GluN2 subunit expression is regulated both spatially
and temporally (Monyer et al., 1994), and it is the identity of
the GluN2 subunits contained within the tetrameric NMDA
receptor complex that determines many of the distinct bio-
physical and pharmacological properties of NMDA receptor
subtypes (see Erreger et al., 2004, Chen and Wyllie, 2006;
Traynelis et al., 2010).
The obligatory requirement of agonist and co-agonist
binding for NMDA receptor activation means that the func-
tion of these receptors can be blocked by antagonists that act
either at the glycine (GluN1-located) site or at the glutamate
(GluN2-located) site. A few NMDA receptor subtype selective
antagonists already exist: non-competitive antagonists such
as ifenprodil (Williams, 1993), R-(R*,S*)-a-(4-hydroxyphenyl)-
b-methyl-4-(phenylmethyl)-1-piperidine propranol (Ro 25–
6981; Fischer et al., 1997) and (1S,2S)-1-(4-hydroxyphenyl)-
2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP 101 606;
Mott et al., 1998) display a selectivity for GluN1/GluN2B
NMDA receptors over other heterodimeric NMDA receptor
combinations that is enough to allow these antagonists to be
used to probe effectively NMDA receptor subunit composition
and function in native neurones. However an antagonist
that selectively blocks the GluN1/GluN2A receptor com-
bination while sparing other NMDA receptor subtypes is
lacking. Although (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-
(2,3- dioxo- 1,2,3,4- tetrahydroquinoxalin-5- yl ) - methyl ] -
phosphonic acid (NVP-AAM077; Auberson et al., 2002) shows
increased potency at GluN2A- over GluN2B-containing
NMDA receptors, the difference in the respective equilibrium
constants is not enough for this antagonist to discriminate
unambiguously between these two receptor combinations
(Frizelle et al., 2006; Wyllie and Chen, 2007).
A recent study by Bettini et al. (2010) identified a series of
novel NMDA receptor receptor antagonists from a chemical
library of around two million compounds using high-
throughput screening methods. One of their ‘hits’,
N - (cyclohexylmethyl) -2- ({5- [(phenylmethyl)amino]-1,3,4-
thiadiazol-2-yl}thio)acetamide (Figure S1B), referred to as
Compound 13 in their study and now named ‘TCN 213’ by
Tocris Bioscience, was shown to preferentially block GluN2A-
containing over GluN2B-containing NMDA receptors. Their
study demonstrated that antagonism by this compound
could be reversed by increasing glycine but not glutamate
concentrations, suggesting that this antagonist acted at the
GluN1 subunit. This observation in itself raises the notion
that the nature of the interaction of GluN1 and GluN2 sub-
units in tetrameric NMDA receptor complexes may be depen-
dent on the identity of the GluN2 subunit and may confer
distinct pharmacology to the GluN1 subunit. Indeed, this
type of GluN2-dependent pharmacology for agonists acting
at the GluN1 subunit has been reported (Chen et al., 2008).
However, in a binding assay, TCN 213 failed to displace the
GluN1 ligand MDL 105 519, raising the possibility that TCN
213 acts at a site on the GluN1 subunit that is distinct from
the glycine binding site itself. In addition no assessment has
been made of the ability of TCN 213 to antagonize NMDA
receptor-mediated currents using electrophysiological record-
ing techniques. Moreover, assessment of the potency of TCN
213 acting at GluN2A- and GluN2B-containing NMDA recep-
tors under conditions where both receptors are activated to a
similar extent is lacking.
Our study assessed the conditions under which TCN 213
displayed selective antagonism of GluN2A-containing NMDA
receptors and extended the investigation to the study of
native NMDA receptors in cortical neurones to assess the
action of TCN 213 on NMDA-evoked currents and NMDA-
evoked excitotoxic neuronal cell death. Furthermore, we
demonstrated that TCN 213 allowed direct pharmacological
assessment of the expression of GluN2A subunits in develop-
ing cortical neurones in dissociated culture. Our data indicate
that this antagonist and its related sulphonamide derivatives
(Bettini et al., 2010) provide promising novel pharmacologi-
cal tools to investigate NMDA receptor function and permit
new opportunities to monitor developmental changes in
native NMDA receptor subunit composition.
Methods
Plasmid constructs, cRNA synthesis and
receptor expression in oocytes
Nomenclature of NMDA receptor subunits follows Collin-
gridge et al. (2009) and Alexander et al. (2011). The expres-
sion plasmids for rat GluN1-1a (excluding exon 5, including
exons 21 and 22, and referred to here as ‘GluN1’) and GluN2A
subunits have been described previously (Chen et al., 2005).
The cDNA construct containing the rat GluN2B subunit was
a gift from Dr Stephen Traynelis (Emory University, Atlanta,
GA). cRNA for each of the NMDA receptor subunits was
synthesized as run-off transcripts as described previously
(Chen et al., 2005; 2008; Erreger et al., 2007). cRNA amounts
and integrity were estimated by intensity of fluorescence in
ethidium bromide-stained agarose gels. GluN1 and GluN2
cRNAs were mixed at a nominal ratio of 1:1 and diluted with
nuclease-free water to 5 ng·mL-1, prior to injection.
All animal care and experimental procedures complied
with current UK Home Office regulations. Stage V–VI oocytes
were obtained from Xenopus laevis that had been anaesthe-
BJPNMDAR developmental switch monitored by TCN 213
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tized by immersion in a solution of 3-amino-benzoic acid
ethylester (0.5%) and then killed by injection of an overdose
of pentobarbital (0.4 mL of 20% solution) followed by decapi-
tation and exsanguination after the confirmation of loss of
cardiac output. Before injection with cRNA mixtures of inter-
est, the follicular membranes of the oocytes were removed.
After injection oocytes were placed in separate wells of
24-well plates containing a modified Barth’s solution with
the following composition (in mM): NaCl 88, KCl 1, NaHCO3
2.4, MgCl2 0.82, CaCl2 0.44, Ca(NO3)2 0.33, Tris–Cl 15,
adjusted to pH 7.35 with NaOH (Sigma-Aldrich, Poole, UK).
This solution was supplemented with 50 IU·mL-1 penicillin,
50 mg·mL-1 streptomycin (Invitrogen, Paisley, UK) and.
50 mg·mL-1 tetracycline (Sigma-Aldrich). Oocytes were placed
in an incubator (19°C) for 24–48 h to allow for receptor
expression and then stored at 4°C until required for electro-
physiological measurements.
Culture of rat cortical neurones
Cortical neurones from E21 Sprague–Dawley rat embryos
were cultured as described previously (Bading and Greenberg,
1991; Papadia et al., 2008; Martel et al., 2009), except that the
Neurobasal-A growth medium contained B27 (Invitrogen),
1% rat serum (Harlan UK Ltd., Oxon, UK) and 1 mM
glutamine. On the 4th day of culture (DIV 4), 1 mL growth
medium containing 9.6 mM cytosine b-D-arabinofuranoside
hydrochloride (AraC) was added to each well to inhibit glial
cell proliferation. Culture media were replenished every 2
days after DIV 9 by replacing 1 mL of the conditioned media
with 1 mL of fresh growth medium that lacked rat serum but
was supplemented with glucose (10 mM). Prior to the excito-
toxicity assay the cultures were transferred from the growth
medium to a non-trophic medium that lacked glycine. This
non-trophic medium contained 10%MEM (Invitrogen) and a
glycine-free salt-glucose medium (in mM): NaCl 114, KCl 5.3,
MgCl2 1, CaCl2 2, HEPES 10, glucose 30, Na-pyruvate 0.5 with
NaHCO3 (0.2%) and phenol red (0.1%).
Transfection of cortical neurones
Neurones were transfected between DIV 5–9 using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
suggested protocol. b-globin or pCis-GluN2A (Rutter and
Stephenson, 2000) were co-transfected with enhanced green
fluorescent protein (eGFP), to identify transfected cells, in a
ratio of 2:1. Transfection efficiency was approximately 5%
with >99% of eGFP-expressing cells being identified as posi-
tive for the neuronal nuclear antigen (NeuN), while <1% were
positive for glial fibrillary acidic protein (GFAP) (Soriano
et al., 2008). Electrophysiological recordings were made from
transfected neurones 48 h post transfection.
Electrophysiological recordings and solutions
Two-electrode voltage-clamp (TEVC) recordings were made at
room temperature (18–21°C) using a GeneClamp 500
(Molecular Devices, Sunnyvale, CA) from oocytes that were
placed in a solution that contained (in mM) NaCl 115, KCl
2.5, HEPES 10, BaCl2 1.8, EDTA 0.01; pH 7.3 with NaOH.
EDTA was included to chelate contaminating low nanomolar
levels of Zn2+ present in our solutions, which cause a potent
but voltage-independent block of GluN2A-containing NMDA
receptors. Current and voltage electrodes were made from
thin-walled borosilicate glass (GC150TF-7.5, Harvard Appara-
tus, Kent, UK) using a PP-830 electrode puller (Narashige
Instruments, Tokyo, Japan) and, when filled with 0.3 M KCl,
possessed resistances of between 1 and 2 MW. Oocytes were
voltage-clamped at -40 mV. Application of solutions was con-
trolled manually, and data were filtered at 10 Hz and digitized
at 100 Hz via a Digidata 1200 A/D interface (Molecular
Devices) using WinEDR software (Strathclyde Electrophysiol-
ogy Software, Strathclyde University, UK).
Whole-cell NMDA-evoked currents in cultured rat corti-
cal neurones were recorded using an Axopatch 200B ampli-
fier (Molecular Devices) using patch pipettes made from
thick-walled borosilicate glass with a tip resistance of
4–8 MW, which were filled with an ‘internal’ solution that
contained (in mM) potassium gluconate 141, NaCl 2.5,
HEPES 10, EGTA 11; pH 7.3 with KOH. Experiments were
conducted at room temperature (18–21°C) in an ‘external’
solution containing (in mM): NaCl 150, KCl 2.8, HEPES 10,
CaCl2 2, glucose 10, EDTA 0.01; pH to 7.3 with NaOH. Picro-
toxin (50 mM) and tetrodotoxin (300 nM) were included to
block GABAA receptor-mediated responses and action
potential-driven excitatory/inhibitory postsynaptic events
respectively. Access resistances (17.9  1.1 MW) were moni-
tored and, recordings where this changed by >20% were dis-
carded. Currents were filtered at 2 kHz and digitized at 5 kHz
via a BNC-2090A/PCI-6251 DAQ board interface (National
Instruments, Austin, TX) and analysed using WinEDR soft-
ware (Dr John Dempster, University of Strathclyde, Glasgow,
UK).
Assessment of antagonist potencies
Concentrations of TCN 213 and 5,7 dichlorokynurenic acid
(5,7 DCKA) required to inhibit 50% (IC50) of agonist-evoked
responses were determined by fitting inhibition curves with
the following equation:
I I n= + ( )( )[B]0 50 H[B] IC ,1
where nH is the Hill coefficient, I[B]0 is the predicted current in
the absence of antagonist and [B] is the concentration of the
antagonist. Each data point was then normalized to the pre-
dicted maximum of the dose–response curve. These normal-
ized values were then pooled and averaged for each construct
and fitted again with this same equation, with the maximum
and minimum for each curve being constrained to asymptote
to 1 and 0 respectively (Wrighton et al., 2008; Otton et al.,
2011). We estimated the equilibrium constant (KB) for TCN
213 acting at GluN1/GluN2A NMDA receptors using the
Schild method (Arunlakshana and Schild, 1959; Wyllie and
Chen, 2007). Briefly, dose ratios (r) from individual oocytes
were determined at low agonist concentrations by construct-
ing a partial concentration–response curve generated in the
absence of antagonist and in the presence of a series of
increasing antagonist concentrations. Each series of two-
point concentration–response curves were plotted on a log–
log scale, and each data set was fitted with a straight line with
the same slope. These parallel fits were used to calculate an
overall mean r-value for each antagonist concentration (3, 10
and 30 mM), which were then used to construct a Schild plot
(Frizelle et al., 2006; Otton et al., 2011; Figure S2). For tech-
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nical reasons, the dose ratio estimate for the highest concen-
tration of TCN 213 (30 mM) had to be determined in a
separate set of experiments from those carried out for the
lower two concentrations (3 and 10 mM).
NMDA-induced excitotoxicity assay
To assess NMDA-induced cell death, neurones were exposed
to NMDA (40 mM + glycine, 1.5 mM) for 1 h in the absence or
presence of either ifenprodil (3 mM), 5,7 DCKA (10 mM) or
TCN 213 (10 mM). Exposure to excitotoxic concentrations of
NMDA leads to neurones displaying swollen cell bodies and
pyknotic nuclei with small irregular chromatin inclusions.
Such characteristics are indicative of necrotic, as opposed to
apopotic, cell death (Fujikawa et al., 2000; Hardingham et al.,
2002). Assessment of cell death was made 24 h after exposure
to NMDA by calculating the ratio of 4′, 6-diamidino-2-phenyl
indole-stained pyknotic nuclei as a percentage of the total
nuclei.
Statistical analysis
Results are presented as mean  SEM, and statistical compari-
son between data sets was assessed using either Student’s
t-test (paired where appropriate) or ANOVA tests to determine
whether differences between mean values were significant
(P < 0.05). Microcal Origin v6.0 software (Microcal,
Northampton, MA, USA) was used for graphical presentation.
Materials
Glutamate and glycine were purchased from Sigma-Aldrich.
N - (cyclohexylmethyl) -2- ({5- [(phenylmethyl)amino]-1,3,4-
thiadiazol-2-yl}thio)acetamide (TCN 213) was originally
purchased from Enamine (Kiev, Ukraine) and subsequently
from Tocris Bioscience (Bristol, UK). 5,7 DCKA, N-methyl-D-
aspartate, ifenprodil, picrotoxin and tetrodotoxin were pur-
chased from Tocris Bioscience. Stock solutions of TCN 213
were made by dissolving the antagonist in DMSO. We con-
firmed in a series of preliminary experiments that DMSO at
the highest final concentration present in our experiments
(0.3%) did not have any effect on the magnitude of NMDA
receptor-mediated responses (data not shown).
Results
Antagonism of NMDA receptor-mediated
responses by TCN 213 is dependent on
glycine concentration
The study of Bettini et al. (2010) suggested that the antago-
nist action of TCN 213 was in part mediated by inhibition of
glycine binding at NMDA receptors. In order to assess this, we
conducted a series of initial experiments to determine
whether the extent of the antagonism produced by TCN 213
was dependent on the concentration of glycine and/or
glutamate used to evoke NMDA receptor-mediated currents.
Figure 1A (upper panel) shows a series of representative TEVC
current traces obtained from an oocyte expressing GluN1/
GluN2A NMDA receptors in response to application of
glutamate (100 mM) and three different concentrations of
glycine (0.1, 1 and 10 times its EC50 value; Chen et al., 2008).
As can be seen from the traces, the extent of the block pro-
duced by TCN 213 (10 mM) was dependent on the glycine
concentration. Almost complete block of the current was
seen when glycine is present at 150 nM (0.1 ¥ EC50), whereas
substantially less block was seen when glycine is present at
15 mM (10 ¥ EC50). Mean data, indicating the extent of the
block of steady-state responses, from a series of similar experi-
ments (n = 6) are illustrated in Figure 1C. In contrast and as
illustrated in the lower panel of Figure 1A, TCN 213 antago-
nism was not dependent on the glutamate concentration
used to evoke NMDA receptor-mediated currents. In these
experiments, glutamate was applied at concentrations again
corresponding to 0.1, 1 and 10 times its EC50 value (Erreger
et al., 2007), while glycine (50 mM) was present at a maximal
concentration. Mean data from a series of experiments (n = 6)
examining the effect of glutamate concentration are illus-
trated in Figure 1D. The extent of the inhibition produced by
TCN 213 was not significantly different for any of the
glutamate concentrations (F2,15 = 0.76, P = 0.48; one-way
ANOVA).
Next we carried out the same two sets of experiments as
described above but recording from oocytes expressing
GluN1/GluN2B NMDA receptors. As it exemplified by the
upper panel in Figure 1B, TCN 213 (10 mM) only modestly
antagonized responses even when the glycine concentration
was low (0.1 ¥ EC50 value) with the mean data from a series of
similar experiments (n = 6) plotted next to the corresponding
GluN1/GluN2A dataset in the bar graph illustrated in
Figure 1C. For GluN2B-containing NMDA receptors, the
extent of the inhibition produced by TCN 213 is not signifi-
cantly different for any of these glycine concentrations
(F2,15 = 0.74, P = 0.49; one-way ANOVA). In addition, in the
presence of 50 mM glycine, no antagonism by TCN 213
was observed at three different glutamate concentrations
(Figure 1B, lower panel, Figure 1D).
IC50 values for TCN 213 and 5,7 DCKA
acting at GluN1/GluN2A and
GluN1/GluN2B NMDA receptors
The experiments illustrated in Figure 1 each examined the
effects of TCN 213 at a fixed concentration (10 mM). In order
to quantify its antagonist potency at GluN2A- and GluN2B-
containing NMDA receptors, we carried out a series of experi-
ments to determine concentrations of TCN 213 that
produced 50% inhibition (IC50 values) of glutamate/glycine
evoked currents. For comparison, we calculated comparable
values for the prototypical glycine-site antagonist, 5,7 DCKA.
As IC50 values are dependent on the agonist concentration
(see Wyllie and Chen, 2007), we again used equipotent con-
centrations of glycine based on its EC50 value when acting at
GluN1/GluN2A and GluN1/GluN2B NMDA receptors (Chen
et al., 2008). Thus, for GluN2A-containing NMDA receptors,
IC50 values were determined at 0.15, 1.5 and 15 mM glycine
(+100 mM glutamate) representing 0.1, 1 and 10 times its EC50
value respectively. Mean inhibition curves for TCN 213 acting
at GluN1/GluN2A NMDA receptors are illustrated in
Figure 2A. As is to be expected, the IC50 values for TCN 213
(Table 1) increased with increasing glycine concentrations for
GluN1/GluN2A NMDA receptors. However, for GluN1/
GluN2B NMDA receptors (Figure 2B), we observed negligible
inhibition of currents when glycine was applied at 1 and 10
BJPNMDAR developmental switch monitored by TCN 213
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times its EC50 value even when TCN 213 was applied at
30 mM. Indeed, we were unable to determine an IC50 value
even for the lowest glycine concentration applied (75 nM =
0.1 ¥ EC50). Thus, TCN 213 appears to preferentially block
GluN1/GluN2A over GluN1/GluN2B NMDA receptors and
inasmuch as our data can be compared with the high-
throughput screening assays reported previously, this antago-
nist does discriminate effectively between GluN2A- and
GluN2B-containing NMDA receptors (Bettini et al., 2010). In
direct comparison, inhibition curves for the prototypical
glycine site antagonist, 5,7 DCKA, were similar when it was
used to block responses mediated by GluN1/GluN2A and
GluN1/GluN2B NMDA receptors (Figure 2C,D). The IC50
values for 5,7 DCKA obtained at each of the glycine concen-
trations are reported in Table 1.
Schild analysis of TCN 213 antagonism
of GluN1/GluN2A NMDA
receptor-mediated currents
While IC50 values are commonly reported to describe the
potency of an antagonist, they suffer from the fact that they
are dependent on both the nature and the concentration of
Figure 1
TCN 213 antagonism of NMDA receptor-mediated responses is both subtype- and glycine-dependent. (A) Upper panel, TEVC currents recorded
from an oocyte expressing GluN1/GluN2A NMDA receptors in response to application of glutamate (100 mM) and glycine, which was applied at
a concentration indicated as a multiple of its EC50 value (1.5 mM for GluN1/GluN2A NMDA receptors). TCN 213 (10 mM) was applied as indicated
and inhibited the glutamate/glycine evoked response, but the extent of the inhibition was dependent on the glycine concentration. Lower panel,
a series of similar TEVC current traces but recorded in the presence of a saturating concentration of glycine (50 mM) and variable concentrations
of glutamate. The extent of the inhibition produced by TCN 213 is similar in each case. (B) A series of representative TEVC current traces illustrating
similar experiments to those shown in panel A but for recordings made from oocytes expressing GluN1/GluN2B NMDA receptors. Note here the
modest inhibition produced by TCN 213. (C) Bar graphs summarizing the mean data obtained from a series of experiments (n = 6) that
investigated the glycine dependency of TCN 213 antagonism of steady-state responses at both GluN1/GluN2A and GluN1/GluN2B NMDA
receptors. (D) As in panel C but for experiments where the glycine concentration was fixed (50 mM) and glutamate was applied at 0.1, 1 and 10
times its EC50 concentration. Calibration bars for TEVC traces illustrated in panels A and B: 750 nA, 50 s.
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the agonist used to evoked the response to be antagonized
(see Wyllie and Chen, 2007). Schild analysis (Arunlakshana
and Schild, 1959) does not have such limitations, and we
have used this method to determine the equilibrium constant
(KB) for TCN 213 acting at GluN1/GluN2A NMDA receptors.
Figure 3A shows a series of pairs of TEVC current traces
recorded in the absence or the presence of TCN 213 (3, 10 or
30 mM). In all recordings, the glutamate concentration was
fixed at 100 mM to ensure full occupancy of its binding site on
the GluN2A NMDA receptor subunit, and we attempted to
match the magnitude of the responses recorded in the
absence of TCN 213 by increasing the concentration of
glycine that was co-applied with TCN 213. Figure 3B shows
the ‘two-point’ concentration–response curves obtained from
the TEVC current traces like those illustrated in Figure 3A and
from which we estimated the dose ratio (r) for each antago-
nist concentration. Pooling data from a series of similar
experiments gave mean r-values of 1.31  0.17, 5.20  0.79
and 17.22  1.69 for 3, 10 and 30 mM TCN 213 respectively
(n = 5, 5 and 4). The resulting Schild plot obtained from these
data is shown in Figure 3C, and a linear fit of the data points
with the slope constrained to be unity gave a KB value of 2.06
 0.17 mM. We also estimated the KB value by simply calcu-
lating the value from the Schild equation using the individual
r-values obtained from individual experiments – this gave a
mean value of 2.2  0.2 mM, whilst confirming that the
individual estimates of such KB values were independent of
the antagonist concentration (F2,11 = 1.13, P = 0.36; one-way
ANOVA). A potential limitation of our use of low agonist con-
centrations to generate ‘two-point’ dose–response curves is
that while these allow us to assess parallel shifts in the dose–
response curves, it does not allow us to determine whether
Figure 2
Inhibition curves for TCN 213 and 5,7 DCKA antagonism of GluN1/GluN2A and GluN1/GluN2B NMDA receptor-mediated responses. (A) Mean
inhibition curves for TCN 213 block of GluN1/GluN2A NMDA receptor-mediated currents. Currents were evoked by glutamate (100 mM) and
glycine (0.1 ¥ EC50; EC50,or 10 ¥ EC50). The data points were fitted with the Hill equation (see Methods), and the mean IC50 values are indicated
by the vertical dashed lines. (B) Summary of the mean inhibition of GluN1/GluN2B NMDA receptor-mediated currents by TCN 213. The low
potency of TCN 213 at this receptor combination prevented the estimation of an IC50 value at any of the glycine concentrations used. (C, D) as
in panel A but for 5,7 DCKA antagonism of GluN1/GluN2A or GluN1/GluN2B NMDA receptor-mediated currents respectively. The mean IC50
values for TCN 213 and 5,7 DCKA antagonism are reported in Table 1.
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antagonism is surmountable as would be anticipated for a
competitive antagonist. We therefore carried out a further set
of experiments to show that antagonism by TCN 213 of a
response evoked by maximal concentrations of both
glutamate (100 mM) and glycine (50 mM) could be overcome
by increasing the glycine concentration. The results from
these experiments are summarized in Figure 3D.
TCN 213 and native GluN2B-containing
NMDA receptors
The experiments described so far have only examined the
effect of TCN 213 on heterologously expressed recombinant
NMDA receptors where the subunit composition of the popu-
lation of receptors is known. We next wanted to assess the
ability of TCN 213 to antagonize native NMDA receptors.
NMDA receptor subunit expression displays both temporal
and spatial regulation (Monyer et al., 1994) where in early
post-natal forebrain development the GluN2B subunit expres-
sion is highest and most ubiquitous. We therefore first chose
to study native NMDA receptors in cultures of rat cortical
neurones at a stage (DIV 7–10) where it would be anticipated
that the most prominent NMDA receptor combination is that
formed by GluN1 and GluN2B subunits. Figure 4A (trace on
left) shows a whole-cell current recording from a cortical
pyramidal cell, voltage-clamped at -70 mV, where application
of NMDA (50 mM) in the presence of glycine (1.5 mM) gives an
inward current that was not antagonized by TCN 213 (10 mM).
This glycine concentration was chosen as a priori we did not
know the composition of the NMDA receptor population in
these neurones and considered it better to use a glycine con-
centration that was equivalent to the higher of the EC50 values
for GluN2A- and GluN2B-containing NMDA receptors. The
average inhibition of NMDA receptor-mediated currents
recorded from cortical neurones at this stage of development
was only 2  3% (n = 12 cells from five separate cultures;
Figure 4B). The strong ifenprodil block together with the lack
of TCN 213 block of NMDA receptor-mediated currents in
these neurones is indicative that the majority of NMDA recep-
tors present in these cells are made up of only GluN1 and
GluN2B subunits since with the glycine and TCN 213 concen-
trations used, we would have expected around 75% block of
the current if the population had been made up entirely of
GluN2A-containing NMDA receptors (Figure 2A). Indeed, to
confirm this, we measured the amount of antagonism pro-
duced by ifenprodil (3 mM), the GluN2B-selective antagonist.
Our data indicate that NMDA receptor-mediated currents in
these neurones were strongly inhibited by this blocker
(Figure 4A, trace on right). On average, ifenprodil (3 mM)
blocked NMDA receptor-mediated currents by 72 2% (n = 12
cells from five separate cultures; Figure 4B). This confirms that
the majority of NMDA receptors present in these cells are
made up of only GluN1 and GluN2B subunits (note that
ifenprodil is a non-competitive antagonist that at most blocks
75–80% of the current mediated by GluN1/GluN2B NMDA
receptors). Furthermore, if we restrict our analysis to a subset
of recordings that showed the greatest block by ifenprodil
(78  1%; n = 7 cells from four separate cultures), which will
presumably identify cells with the largest GluN1/GluN2B
NMDA receptor content, the extent of the TCN 213 block is
4  2% (n = 7). Ifenprodil also antagonizes heterotrimeric
NMDA receptors containing GluN1, GluN2A and GluN2B
subunits (Kew et al., 1998; Tovar andWestbrook, 1999; Hatton
and Paoletti, 2005), and this combination is considered to
form a significant population of native NMDA receptors
(Chazot and Stephenson, 1997; Rauner and Köhr, 2011). Nev-
ertheless, the concentration of ifenprodil required to block
such heterotrimeric receptors combination is higher than that
used here. In addition, the extent of the block produced by
ifenprodil (72%) is very similar to the block produced by this
concentration when applied to recombinant NMDA receptors
containing only GluN1 and GluN2B subunits. Thus, in the
conditions studied here (rat cortical neurones, 7–10 DIV),
the vast majority of NMDA receptors are heterodimers of
the GluN1/GluN2B subtype.
In a separate series of experiments, we assessed the ability
of TCN 213 to block NMDA-induced excitoxicity in cortical
cultures (DIV 7–10). We have previously demonstrated that
NMDA-induced cell death in hippocampal neurones at this
stage of development in vitro can be completely attenuated by
ifenprodil indicating that this process is mediated by
GluN2B-containing NMDA receptors (Martel et al., 2009).
Figure 4C shows example images of neuronal cell bodies from
untreated and NMDA (40 mM)-treated cultures. In the
absence of neurotoxic insult, neurones display regularly sized
cell bodies (Figure 4Ci). This is also seen when NMDA is
applied in the presence of ifenprodil (Figure 4Ciii) or the
non-selective GluN1-site antagonist, 5,7 DCKA (Figure 4Civ).
However in the absence of any NMDA receptor antagonists
(Figure 4Cii) or TCN 213 (Figure 4Cv), the presence of a high
percentage of pyknotic cell nuclei is evident. Figure 4D sum-
marizes a series of experiments where we have quantified the
neuroprotective effects of ifenprodil, 5,7 DCKA and TCN 213.
The extent of cell death seen in the presence of TCN 213 was
not significantly different from that seen in cultures treated
with NMDA alone. Both ifenprodil (3 mM) and 5,7 DCKA
(10 mM) reduced significantly the percentage of neurones dis-
playing pyknotic nuclei (P < 0.05 with Bonferroni correction;
n = 3–4 repeats for each condition).
Table 1
IC50 values for TCN 213 and 5,7 DCKA acting at GluN1/GluN2A or
GluN1/GluN2B NMDA receptors, in the presence of different con-
centrations of glycine (gly)
Antagonist IC50 (mM)
TCN 213 5,7 DCKA
GluN1/GluN2A
[gly] = 0.1 EC50 0.55  0.05 (7) 0.13  0.01 (6)
[gly] = EC50 3.5  0.05 (7) 0.42  0.03 (9)
[gly] = 10 EC50 40  3.5 (6) 4.1  0.3 (4)
GluN1/GluN2B
[gly] = 0.1 EC50 n.d. 0.074  0.01 (6)
[gly] = EC50 n.d. 0.49  0.01 (6)
[gly] = 10 EC50 n.d. 4.1  0.4 (6)
Values are given as mean  SEM with the number of experi-
ments given in parentheses.
n.d., not determined.
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TCN 213 antagonism of GluN2A-containing
NMDA receptors in cortical neurones
The experiments illustrated in Figure 4 show that neurones
predominantly express GluN2B-containing NMDA receptors
at DIV 7–10. Thus, in a final series of experiments, we assessed
the ability of TCN 213 to block native NMDA receptors con-
taining GluN2A subunits. For these experiments, we
increased the concentration of glycine (to 3 mM) in our exter-
nal recording as we wanted to increase the proportion of
GluN2A-containing NMDA receptors that would be activated
in this set of experiments. We confirmed, however, that the
effect of this increased glycine concentration did not prevent
us from blocking selectively GluN1/GluN2A over GluN1/
GluN2B NMDA receptors by measuring the extent of TCN
213 antagonism at recombinantly expressed NMDA receptors
(Figure S3A,B). For GluN1/GluN2A NMDA receptors, TCN
213 (30 mM) produced a mean block of 78  4% (n = 5),
whereas at GluN1/GluN2B NMDA receptors only 2  0.5%
(n = 4) of the NMDA-evoked current was antagonized.
To compare TCN 213 block of NMDA-evoked currents
from a similar developmental age with those used in the
Figure 3
Schild analysis of TCN 213 antagonism of GluN1/GluN2A NMDA receptor-mediated responses. (A) Illustration of a set of TEVC current traces,
obtained from an oocyte expressing GluN1/GluN2A NMDA receptors, and used to generate ‘two-point’ dose–response curves in either the
absence or presence of TCN 213. (B) Partial, low-concentration dose–response curves obtained from the TEVC current traces illustrated in panel
A and used to estimate dose ratios (r). The slope of the fitted line to the control responses (no TCN 213) was used to fit the responses obtained
in the presence of 3 mM, 10 mM and 30 mM TCN 213. (C) Schild plot for antagonism by TCN 213 of GluN1/GluN2A NMDA receptors using dose
ratios estimated from a series of experiments (n = 5, 5, 4), such as that illustrated in panel B. The dashed line represents a ‘free’ fit of the data and
has a slope of 1.13. This was considered not to be significantly different from 1 (95% confidence interval: 0.94–1.31) and the solid line is the fit
of the data points to the Schild equation (i.e. the slope of this line is unity). The intercept on the abscissa (where the log10 value of the dose ratio
equals zero) gives an equilibrium constant (KB) value for TCN 213 of 2.06  0.17 mM. (D) Bar graph summary showing that antagonism of
GluN1/GluN2A NMDA receptor-mediated currents is surmountable when the glycine concentration is increased.
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experiments illustrated in Figure 4 but where GluN2A sub-
units were now present, we transfected cortical cultures (DIV
5–9) with a plasmids containing either GluN2A cDNA or
cDNA encoding globin (to act as a control; see Methods). In
a separate series of experiments, we recorded form cortical
neurones at a later developmental stage (DIV 14–17) when
one would anticipate that expression levels of GluN2A sub-
units are increased (Monyer et al., 1994). The results of these
experiments are illustrated in Figure 5. Figure 5A shows
typical whole-cell currents recorded from either a globin-
transfected (upper trace), a GluN2A-transfected (middle trace)
or an older non-transfected (lower trace) cortical neurone.
Control responses to NMDA (50 mM) and glycine (3 mM)
established the magnitude of NMDA receptor-mediated
response in each neurone prior to the application of NMDA
and glycine together with the GluN2B-selective antagonist,
ifenprodil (3 mM). The extent of the ifenprodil block
(Figure 5B) was greatest in globin-transfected neurones and
lower in both GluN2A-transfected neurones and non-
transfected neurones. Once a steady-state response was
obtained in response, we applied TCN 213 (30 mM) to deter-
mine the amount of the remaining current that was sensitive
to this GluN2A-selective antagonist. For TCN 213 antagonism
(Figure 5C), we observed that the mean block was greatest at
GluN2A-transfected neurones and lower at both non-
transfected neurones and globin-transfected neurones.
Figure 4
Activity of TCN 213 at native NMDA receptor-mediated responses in rat cortical cultures (DIV 7–9). (A) Whole-cell current recording made from
a rat cortical pyramidal cell (7 DIV) and voltage-clamped at -70 mV. TCN 213 (10 mM) does not antagonize the NMDA (50 mM) + glycine (1.5 mM)
evoked current, whereas ifenprodil (3 mM) reduces the current by around 75% indicating the presence of a large population of GluN1/GluN2B
NMDA receptors in this neurone. (B) Bar graph summary (n = 12 cells) illustrating the mean TCN 213 and ifenprodil block of NMDA/glycine
evoked currents. (C) Typical micrographs of neurones used to determine the extent of cell death elicited by each of the treatments. Note the high
ratio of pyknotic nuclei compared with non-pyknotic nuclei when neurones are exposed to NMDA (40 mM) in the presence of TCN 213 (10 mM).
Calibration bar 20 mm. (D) Summary of the percentage cell death observed in response to 1 h exposure to NMDA at the concentrations indicated
(+1.5 mM glycine). Note the neuroprotective effects of the GluN1/GluN2B NMDA receptor selective antagonist, ifenprodil (3 mM) and the
non-selective GluN1-site antagonist, 5,7 DCKA (10 mM). TCN 213 (10 mM) is, however, not neuroprotective.
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However, these mean values for ifenprodil and TCN 213
block of NMDA-evoked currents in each of these three cat-
egories of neurones obscure the fact that there was a highly
correlated (R2 = 0.87) relationship between the magnitude of
ifenprodil block and TCN 213 block in each cell we examined
(Figure 5D). Thus, an NMDA-evoked current that showed
high ifenprodil sensitivity was only weakly antagonized by
TCN 213, whereas strong block of currents by TCN 213 was
observed in cells, which showed lower sensitivity to ifen-
prodil. This reciprocal relationship in antagonism by two
NMDA receptor subtype-selective blockers is a key observa-
tion and allows pharmacological profiling of NMDA receptor
subunit composition.
Discussion
Our data demonstrate clearly that TCN 213 showed selective
antagonism of GluN1/GluN2A over GluN1/GluN2B NMDA
receptors. This antagonism could be surmounted by increas-
Figure 5
TCN 213 antagonism of GluN2A-containing cortical neurones. (A) Example whole-cell currents recorded from cortical pyramidal cells voltage-
clamped at -70 mV. Upper left trace: example of an NMDA receptor-mediated current elicited by NMDA (50 mM) in the presence of glycine
(3 mM) and recorded from a globin-transfected (control) pyramidal neurone (DIV 7). The trace to the right illustrates the NMDA receptor-mediated
current recorded from the same cell and to the same concentrations of NMDA and glycine but also in the presence of the GluN2B-selective
antagonist, ifenprodil (3 mM). Once a steady-state response was established, TCN 213 (30 mM) was applied to determine the amount of the
ifenprodil-unblocked current that was sensitive to this GluN2A-selective antagonist. Middle and lower traces: examples of whole-cell currents
recorded from either a GluN2A-transfected (DIV 7; middle trace) or non-transfected (DIV 14; lower trace) pyramidal neurone using the same drug
application protocol as described above. (B) Bar graph summaries illustrating the mean ifenprodil block of NMDA receptor-mediated currents
recorded from neurones in each of the three categories described in panel A. Ifenprodil block is greatest in young (DIV 7–11) neurones transfected
with globin (n = 8), and this is significantly greater (P < 0.01, t-test with Bonferroni correction) than the ifenprodil block of NMDA-induced currents
in either GluN2A-transfected (n = 7) or older (DIV 14–17; n = 13) pyramidal neurones. (C) Equivalent bar graph summaries to those illustrated
in panel B, but for TCN 213 block of NMDA receptor-mediated currents. In this case TCN 213 antagonism is observed to be the greatest at
GluN2A-transfected neurones and weakest at globin-transfected neurones. (D) Plot illustrating the extent of ifenprodil and TCN 213 antagonism
(in the same cell) of NMDA-evoked currents. While a wide range in the amount of block produced by either ifenprodil or TCN 213 is observed
(particularly for recordings from GluN2A-transfected and from neurones in older cultures), there is a strong (negative) correlation (R2 = 0.87)
between the amount of block produced by ifenprodil and TCN 213.
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ing the concentration of glycine but not glutamate present in
the external recording solution. Over the concentration
range examined, Schild analysis of TCN 213 antagonism gave
a Schild plot with unity slope, which is indicative of com-
petitive antagonism (but see below for further discussion).
Our observations are not only consistent with some of those
made in the study of Bettini et al. (2010) but also extend these
earlier findings as we have calculated for the first time a KB
value for TCN 213 acting at GluN1/GluN2A NMDA receptors.
In addition, we show that TCN 213 permits direct pharma-
cological identification of functional NMDA receptors con-
taining GluN2A subunits and thus will have considerable
utility for the study of, and changes in, NMDA receptor
composition.
TCN 213 permits pharmacological profiling
of developmental changes in native NMDA
receptor subunit composition
Early studies describing the in situ expression of mRNA levels
of GluN1 and GluN2 subunits indicated both spatial and
temporal control of NMDA receptor subtypes (Monyer et al.,
1994). Indeed, developmental changes in the subunit com-
position of native NMDA receptors are well-documented in,
for example, cortical neurones (Carmignoto and Vicini, 1992;
Hestrin, 1992; Sheng et al., 1994; Crair and Malenka, 1995;
Flint et al., 1997; Stocca and Vicini, 1998) cerebellar neurones
(Farrant et al., 1994) and striatal neurones (Logan et al., 2007;
Brothwell et al., 2008). For cortical neurones, NMDA receptor
composition switches from a population made up from pre-
dominantly GluN1 and GluN2B subunits to ones that are
heterodimeric combinations of GluN1 and GluN2A, and
GluN1 and GluN2B subunits as well as heterotrimeric com-
binations of each of these three subunits. The evidence for
such changes in subunit composition comes from changes in
the kinetics of glutamatergic synaptic currents, protein and
mRNA expression levels, co-immunoprecipitation with
subunit-specific antibodies and the sensitivity of NMDA
receptor-mediated currents to selective GluN2B antagonists
(see van Zundert et al., 2004). What has been lacking, to date,
is the ability to block selectively NMDA receptors comprising
of GluN1 and GluN2A subunits. Although competitive
antagonists such as NVP-AAM077 show some selectivity for
GluN1/GluN2A over GluN1/GluN2B NMDA receptors (Aub-
erson et al., 2002), this selectivity is not enough to allow
unequivocal NMDA receptor subunit identification (Frizelle
et al., 2006). Therefore, novel ligands such as TCN 213
and 3-chloro-4-fluoro-N-[4-[[2-(phenylcarbonyl)hydrazino]
carbonyl]benzyl] benzenesulphonamide (Bettini et al., 2010),
with their greater selectivity, offer greater potential for eluci-
dation of NMDA receptor composition. Our data clearly show
that for cortical neurones at early developmental stages (DIV
7–10), the vast majority of NMDA receptors are comprised of
only GluN1 and GluN2B subunits since their sensitivity to
ifenprodil is very similar to that seen with recombinant
GluN1/GluN2B NMDA receptors. The range of ifenprodil and
TCN 213 block in older cultures (DIV 14–17) indicates that
this population of neurones express both GluN2A- and
GluN2B-containing NMDA receptors. Our data do not
address directly the proportion of NMDA receptors that are
triheteromeric complexes of GluN1, GluN2A and GluN2B
subunits (Chazot and Stephenson, 1997; Rauner and Köhr,
2011) as we do not know how effective TCN 213 is at block-
ing such receptor combinations. Nevertheless, comparison
with our data from recombinant NMDA receptors indicates,
for recordings where TCN 213 blocked around 50% of the
current remaining following the application of ifenprodil,
that heterotrimeric complexes are unlikely to represent the
majority of NMDA receptors in the total population.
The nature of TCN 213 subtype selective
NMDA receptor antagonism of
GluN1/GluN2A NMDA receptors
Our data show that TCN 213 can produce complete block of
GluN1/GluN2A NMDA receptor-mediated responses, while
sparing responses mediated by GluN1/GluN2B NMDA recep-
tors. However, this was only achieved when the glycine con-
centration was low (0.1 ¥ EC50; Figure 3A,B). At higher glycine
concentrations, complete block of GluN1/GluN2A NMDA
receptors was not achieved, although the selectivity of TCN
213 is still sufficient to discriminate very effectively between
GluN1/GluN2A and GluN1/GluN2B NMDA receptors (Fig-
ure S3). It could be argued that one need only increase the
concentration of antagonist to overcome higher concentra-
tions of glycine. However, extrapolation of our data
(Figure 2A) shows that for a glycine concentration that is 10
times its EC50 value, it is predicted that a concentration of
around 1 mM TCN 213 would be required to block fully a
GluN1/GluN2A NMDA receptor-mediated response. It
remains unclear whether at such high concentration if TCN
213 would still retain selectivity of GluN1/GluN2A NMDA
receptor-mediated responses over those mediated by GluN2B-
containing NMDA receptors, notwithstanding that the solu-
bility of TCN 213 would make it unlikely that such high
concentrations could be used effectively.
Let us now consider how the selectivity of TCN 213 for
GluN1/GluN2A NMDA receptors may come about. The
glycine dependency of the IC50 values for TCN 213, the Schild
analysis giving a unity slope and the fact that the antagonism
can be surmounted and a maximum response retained by
increasing the glycine concentration are consistent with the
notion that TCN 213 is a competitive, reversible antagonist
that acts at the GluN1 glycine binding site. Why therefore is
TCN 213 selective for GluN1/GluN2A over GluN1/GluN2B
NMDA receptors as they both contain the same GluN1
subunit? A potential explanation for this could be that the
conformation or accessibility of the site to which TCN 213
binds is different when GluN1 is associated with GluN2A or
GluN2B NMDA receptor subunits. Our previous work (Chen
et al., 2008) has documented the relative potencies of a series
of GluN1 (glycine site) full and partial agonists for each of the
four NMDA receptor subtypes. These data showed that for all
agonists the rank order of potency was GluN1/GluN2D >
GluN1/GluN2C > GluN1/GluN2B > GluN1/GluN2A. These
data refer to potencies of agonist where the EC50 value reflects
all the rate constants governing ‘binding’ and ‘gating’ steps in
the reaction scheme that describes the activation of the recep-
tor. Indeed, our data concerning the actions of agonists at the
GluN1 NMDA receptor subunit suggested that differences in
the potencies of glycine-site agonists were due to interactions
between amino acids at the interface of GluN1 and GluN2
NMDA receptor subunits, and that this most likely contrib-
uted to altered ‘gating’ of GluN1-dependent reactions when
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GluN1 was co-expressed with each of the GluN2 NMDA
receptor subunits. This interpretation was consistent with our
findings from Schild analysis, which indicated that the KB
values for 5,7 DCKA at GluN1/GluN2A and GluN1/GluN2D
NMDA receptors were indistinguishable (Chen et al., 2008).
Thus, 5,7 DCKA binds to the GluN1 site in GluN1/GluN2A
and GluN1/GluN2D NMDA receptors with equal affinity
despite the fact there is a 10-fold difference in the potency of
glycine at GluN1/GluN2A and GluN1/GluN2D NMDA recep-
tors. Nevertheless, two derivatives of 5,7 DCKA do exhibit
some subtype selectivity for GluN2A- and GluN2B-
containing NMDA receptors. L-689 560 (Hess et al., 1996)
shows a modest (5-fold) selectivity for GluN2A- over GluN2B-
containing NMDA receptors, whereas CGP-61594 (Honer
et al., 1998) is 10-fold more potent at GluN1/GluN2B NMDA
receptors compared with GluN1/GluN2A NMDA receptors.
Our data for TCN 213 were quite different and suggested a far
greater selectivity of TCN 213 than those reported for those
antagonists based on the 5,7 DCKA structure. While the data
illustrated in Figure 2B do not allow any estimation of an IC50
value for TCN 213 acting at GluN1/GluN2B NMDA receptors,
we would estimate that the IC50 value would need to be in
excess of 300 mM (for glycine concentration equal to its EC50).
This would indicate a selectivity of around 100-fold, which is
considerably greater than that reported for antagonists based
on the 5,7 DCKA structure.
We need also to consider an alternative explanation for
the antagonism produced by TCN 213. The study of Bettini
et al. (2010) showed that TCN 213 failed to displace the
GluN1 ligand MDL 105 519, which can be taken to indicate
that TCN 213 does not act competitively (i.e. mutually exclu-
sive binding with glycine), but rather that it acts allosteri-
cally to modulate glycine binding in a manner which cannot
be distinguished by the types of experiments we have carried
out in the present study. For example, if TCN 213 caused an
increase in the dissociation rate of glycine from its binding
site on the GluN1 subunit, then our experiments and the
limited concentration range of TCN 213 we have used could
not distinguish between this alternative mode of action and
competitive, reversible antagonism (SF Traynelis, K Hansen
and K Odgen, pers. comm.). Evidence for either a competi-
tive antagonist mechanism or an allosteric modulation of
glycine (un)binding will be provided from studies examining
crystal structures bound with TCN 213 and detailed investi-
gations of the kinetics of TCN 213 blocking and unblocking
rates.
Conclusion
While precise details concerning the mode of action of TCN
213 remain, it is clear that this ligand and the related sulpho-
namide derivatives (Bettini et al., 2010; Ogden and Traynelis,
2011) offer us new pharmacological tools to probe NMDA
receptor function and specifically afford us the opportunity
to antagonize selectively GluN1/GluN2A NMDA receptors.
Our study took advantage of this selective antagonism by
TCN 213 and allowed us to use a pharmacological approach
to monitor directly changes in subunit composition in func-
tional NMDA receptors in developing cortical neurones.
Acknowledgements
This work was supported by the funds from The Wellcome
Trust and the Honours Programmes in Pharmacology and
Neuroscience at The University of Edinburgh. We thank Matt
Livesey for constructive comments on the manuscript and
Steve Traynelis, Kasper Hansen and Kevin Ogden (Emory
University) for helpful discussions and for sharing unpub-
lished data.
Conflicts of interest
The authors state no conflict of interest.
References
Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and
Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1):
S1–S324.
Arunlakshana O, Schild HO (1959). Some quantitative uses of drug
antagonists. Br J Pharmacol Chemother 14: 48–57.
Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R,
Schmutz M (2002). 5-Phosphonomethylquinoxalinediones as
competitive NMDA receptor antagonists with a preference for the
human 1A/2A, rather than 1A/2B receptor composition. Bioorg
Med Chem Lett 12: 1099–1102.
Bading H, Greenberg ME (1991). Stimulation of protein tyrosine
phosphorylation by NMDA receptor activation. Science 253:
912–914.
Bettini E, Sava A, Griffante C, Carignani C, Buson A, Capelli A et al.
(2010). Identification and characterization of novel NMDA receptor
antagonists selective for NR2A- over NR2B-containing receptors.
J Pharmacol Exp Ther 335: 636–644.
Brothwell SL, Barber JL, Monaghan DT, Jane DE, Gibb AJ, Jones S
(2008). NR2B- and NR2D-containing synaptic NMDA receptors in
developing rat substantia nigra pars compacta dopaminergic
neurones. J Physiol 586: 739–750.
Carmignoto G, Vicini S (1992). Activity-dependent decrease in
NMDA receptor responses during development of the visual cortex.
Science 258: 1007–1011.
Chazot PL, Stephenson FA (1997). Molecular dissection of native
mammalian forebrain NMDA receptors containing the NR1 C2
exon: direct demonstration of NMDA receptors comprising NR1,
NR2A, and NR2B subunits within the same complex. J Neurochem
69: 2138–2144.
Chen PE, Wyllie DJA (2006). Pharmacological insights obtained
from structure-function studies of ionotropic glutamate receptors.
Br J Pharmacol 147: 839–853.
Chen PE, Geballe MT, Stansfeld PJ, Johnston AR, Yuan H, Jacob AL
et al. (2005). Structural features of the glutamate binding site in
recombinant NR1/NR2A N-methyl-D-aspartate receptors determined
by site-directed mutagenesis and molecular modeling. Mol
Pharmacol 67: 1470–1484.
Chen PE, Geballe MT, Katz E, Erreger K, Livesey M, O’Toole KK
et al. (2008). Modulation of glycine potency in rat recombinant
NMDA receptors containing chimeric NR2A/2D subunits expressed
in Xenopus laevis oocytes. J Physiol 586: 227–245.
BJPNMDAR developmental switch monitored by TCN 213
British Journal of Pharmacology (2012) 166 924–937 935
Collingridge GL, Olsen RW, Peters JA, Spedding M (2009). A
nomenclature for ligand-gated ion channels. Neuropharmacology
56: 2–5.
Crair MC, Malenka RC (1995). A critical period for long-term
potentiation at thalamocortical synapses. Nature 375: 325–328.
Erreger K, Chen PE, Wyllie DJA, Traynelis SF (2004). Glutamate
receptor gating. Crit Rev Neurobiol 16: 187–224.
Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ
et al. (2007). Subunit-specific agonist activity at NR2A, NR2B,
NR2C, and NR2D containing N-methyl-D-aspartate glutamate
receptors. Mol Pharmacol 72: 907–920.
Farrant M, Feldmeyer D, Takahashi T, Cull-Candy SG (1994).
NMDA-receptor channel diversity in the developing cerebellum.
Nature 368: 335–339.
Fischer G, Mutel V, Trube G, Malherbe P, Kew JNC, Mohacsi E et al.
(1997). Ro- 25–6981, a highly potent and selective blocker of
N-methyl-D-aspartate receptors containing the NR2B subunit.
Characterisation in vitro. J Pharmacol Exp Ther 283: 1285–1292.
Flint AC, Maisch US, Weishaupt JH, Kriegstein AR, Monyer H
(1997). NR2A Subunit expression shortens NMDA receptor synaptic
currents in developing neocortex. J Neurosci 17: 2469–2476.
Frizelle PA, Chen PE, Wyllie DJA (2006). Equilibrium constants
for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,
4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid
(NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B
N-methyl-D-aspartate receptors: implications for studies of synaptic
transmission. Mol Pharmacol 70: 1022–1032.
Fujikawa DG, Shinmei SS, Cai B (2000). Kainic acid-induced
seizures produce necrotic, not apoptotic, neurons with
internucleosomal DNA cleavage: implications for programmed cell
death mechanisms. Neuroscience 98: 41–53.
Hardingham GE, Fukunaga Y, Bading H (2002). Extrasynaptic
NMDARs oppose synaptic NMDARs by triggering CREB shut-off and
cell death pathways. Nat Neurosci 5: 405–414.
Hatton CJ, Paoletti P (2005). Modulation of triheteromeric NMDA
receptors by N-terminal domain ligands. Neuron 46: 261–274.
Hess SD, Daggett LP, Crona J, Deal C, Lu CC, Urrutia A et al.
(1996). Cloning and functional characterization of human
heteromeric N-methyl-D-aspartate receptors. J Pharmacol Exp Ther
278: 808–816.
Hestrin S (1992). Developmental regulation of NMDA receptor
mediated synaptic currents at a central synapse. Nature 357:
686–689.
Honer M, Benke D, Laube B, Kuhse J, Heckendorn R, Allgeier H
et al. (1998). Differentiation of glycine antagonist sites of
N-methyl-D-aspartate receptor subtypes. Preferential interaction of
CGP 61594 with NR1/2B receptors. J Biol Chem 273: 11158–11163.
Johnson JW, Ascher P (1987). Glycine potentiates the NMDA
response in cultured mouse brain neurons. Nature 325: 529–531.
Kew JN, Richards JG, Mutel V, Kemp JA (1998). Developmental
changes in NMDA receptor glycine affinity and ifenprodil
sensitivity reveal three distinct populations of NMDA receptors in
individual rat cortical neurons. J Neurosci 18: 1935–1943.
Kleckner NW, Dingledine R (1988). Requirement for glycine in
activation of NMDA-receptors expressed in Xenopus oocytes.
Science 241: 835–837.
Logan SM, Partridge JG, Matta JA, Buonanno A, Vicini S (2007).
Long-lasting NMDA receptor-mediated EPSCs in mouse striatal
medium spiny neurons. J Neurophysiol 98: 2693–2704.
Martel MA, Wyllie DJ, Hardingham GE (2009). In developing
hippocampal neurons, NR2B-containing NMDA receptors can
mediate signalling to neuronal survival and synaptic potentiation,
as well as neuronal death. Neuroscience 158: 334–343.
Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H
et al. (1992). Heteromeric NMDA receptors: molecular and
functional distinctions of subtypes. Science 256: 1217–1221.
Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994).
Developmental and regional expression in the rat brain and
functional properties of four NMDA receptors. Neuron 12: 529–540.
Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ,
Lyuboslavsky P et al. (1998). Phenylethanolamines inhibit NMDA
receptors by enhancing proton inhibition. Nat Neurosci 1: 659–667.
Ogden KK, Traynelis SF (2011). New advances in NMDA receptor
pharmacology. Trends Pharmacol Sci 32: 726–733.
Otton HJ, Lawson McLean A, Pannozzo MA, Davies CH, Wyllie DJA
(2011). Quantification of the Mg2+-induced potency shift of
amantadine and memantine voltage-dependent block in human
recombinant GluN1/GluN2A NMDARs. Neuropharmacology 60:
388–396.
Papadia S, Soriano FX, Léveillé F, Martel MA, Dakin KA, Hansen HH
et al. (2008). Synaptic NMDA receptor activity boosts intrinsic
antioxidant defences. Nat Neurosci 11: 476–487.
Rauner C, Köhr G (2011). Triheteromeric NR1/NR2A/NR2B
receptors constitute the major N-methyl-D-aspartate receptor
population in adult hippocampal synapses. J Biol Chem 286:
7558–7566.
Rutter AR, Stephenson FA (2000). Coexpression of postsynaptic
density-95 protein with NMDA receptors results in enhanced
receptor expression together with a decreased sensitivity to
L-glutamate. J Neurochem 75: 2501–2510.
Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY (1994).
Changing subunit composition of heteromeric NMDA receptors
during development of rat cortex. Nature 368: 144–147.
Soriano FX, Martel MA, Papadia S, Vaslin A, Baxter P, Rickman C
et al. (2008). Specific targeting of pro-death NMDA receptor signals
with differing reliance on the NR2B PDZ ligand. J Neurosci 28:
10696–10710.
Stocca G, Vicini S (1998). Increased contribution of NR2A subunit
to synaptic NMDA receptors in developing rat cortical neurons.
J Physiol 507: 13–24.
Sugihara H, Moriyoshi K, Ishri T, Masu M, Nakanishi S (1992).
Structures and properties of seven isoforms of the NMDA receptor
generated by alternative splicing. Biochem Biophys Res Commun
185: 826–832.
Tovar KR, Westbrook GL (1999). The incorporation of NMDA
receptors with a distinct subunit composition at nascent
hippocampal synapses in vitro. J Neurosci 19: 4180–4188.
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM,
Ogden KK et al. (2010). Glutamate receptor ion channels: structure,
regulation and function. Pharmacol Rev 62: 405–496.
Williams K (1993). Ifenprodil discriminates subtypes of the
N-methyl-D-aspartate receptor: selectivity and mechanisms at
recombinant heteromeric receptors. Mol Pharmacol 44: 851–859.
Wrighton DC, Baker EJ, Chen PE, Wyllie DJA (2008). Mg2+ and
memantine block of rat recombinant NMDA receptors containing
chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes.
J Physiol 586: 211–225.
BJP S McKay et al.
936 British Journal of Pharmacology (2012) 166 924–937
Wyllie DJA, Chen PE (2007). Taking the time to study competitive
antagonism. Br J Pharmacol 150: 541–551.
van Zundert B, Yoshii A, Constantine-Paton M (2004). Receptor
compartmentalization and trafficking at glutamate synapses: a
developmental proposal. Trends Neurosci 27: 428–437.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Requirement of glycine for NMDA receptor acti-
vation and structures of the GluN1 NMDA receptor subunit
antagonists, TCN 213 and 5,7 DCKA. (A) TEVC recording
from an oocyte expressing recombinant GluN1/GluN2A
NMDA receptors and voltage-clamped at -40 mV. Application
of glutamate (100 mM) in the absence of glycine (indicated by
the grey bar and trace) evokes only a small (<20 nA) inward
current. Simultaneous application (indicated by the black
bars) of both glutamate and glycine (50 mM) results in a large
(2.5 mA) inward current. On average, the mean current
evoked by glutamate in the absence of added glycine was
1.2  0.4% (n = 4) of the current recorded when both
glutamate and glycine were present. (B) Structure of the novel
glycine site antagonist, TCN 213, characterized in this study.
(C) Structure of the prototypical glycine site antagonist, 5,7
DCKA.
Figure S2 Schild analysis using two-point dose–response
curves. (A) Del-Castillo–Katz reaction scheme showing mutu-
ally exclusive binding of an agonist, A, and an antagonist, B,
to a receptor, R. The active state of the receptor AR* is reached
via an intermediate liganded but inactive state AR. The
antagonist when bound to R results in the inactive state, BR.
Equilibrium constants for agonist and antagonist binding are
denoted as KA and KB, respectively, while the equilibrium
constant for the isomerization reaction of AR to the AR* state
is denoted by E. In the absence of antagonist and using the
equilibrium constants as shown, the proportion (pAR*) of
receptors in the AR* state has a maximum value (i.e.
E
E1+
)
of 0.5 with an EC50 value (i.e.
K
E
A
1+
) of 1.5 mM. (B) Series of
predicted dose-response curves generated in the absence or
presence of antagonist for the reaction scheme shown in A. In
the presence of the antagonist, the dose–response curves are
shifted in a parallel manner to the right and retain the
maximum response that is achieved in the absence of the
antagonist. In the presence of the antagonist, the EC50 is
shifted by a factor of 1 + cB, where cB =
[ ]B
BK
. (C) The area
enclosed by the dashed grey box in panel B is expanded to
show the profile of the dose–response curves on a conven-
tional semi-log plot (upper graph) and a log–log plot (lower
graph). Note the linear transformation of the data when
log–log scales are used. Since each of the lines are parallel,
dose ratios (r) can easily be obtained by dividing the concen-
tration of agonist required to evoke a response in the pres-
ence of a given antagonist concentration by the agonist
concentration that produces the same response in the
absence of antagonist. Thus, only two data points are
required to define each line on the log-log plot when low
agonist concentrations are used – this is the basis of our
methodology. (D) Schild plot using the dose ratio values
obtained from C. The data points are fitted with a straight
line with unity slope. The intercept on the abscissa recovers
the KB value of 2 mM used in the reaction scheme in panel A.
Figure S3 Antagonism of recombinant NMDA receptors at
higher glycine concentrations. (A) Upper trace: example of
TEVC current trace recorded from an oocyte expressing
GluN1/GluN2A NMDA receptors. NMDA receptors were acti-
vated by NMDA (50 mM) and glycine (3 mM). Application of
TCN 213 (30 mM) results is an approximately 75% reduction
in the amplitude of the current response. Lower trace: TEVC
current recorded under the same conditions but from an
oocyte expressing GluN1/GluN2B NMDA receptors. Note
that TCN 213 produces very little block of the NMDA
receptor-mediated current and therefore at these concentra-
tions of NMDA (50 mM) and glycine (3 mM) discriminates
between these two NMDA receptor subtypes. (B) Bar graph
illustrating the mean block produced by TCN 213 of GluN1/
GluN2A and GluN1/GluN2B NMDA receptor-mediated cur-
rents. On average, GluN1/GluN2A NMDA receptor currents
were blocked by 78  4% (n = 5), whereas GluN1/GluN2B
NMDA receptor currents were blocked by 2  0.5% (n = 4).
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
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